Tigapotide
Regenerative repair
Tissue repair, structural remodeling, or healing support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Regenerative peptide / tissue compound
- Primary mechanism
- Tissue repair, extracellular matrix, collagen, angiogenesis, or cell migration pathways
- Primary market use
- Regenerative repair
Pharmacology
- Molecular weight (Da)
- 2025.15
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 9 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Place in regenerative repair/tissue remodeling comparison clusters.
Notes
Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein ( PTHrP ) in tumors and plasma. Tigapotide reduces plasma calcium levels i...